PhoenixBio Co., Ltd. (TYO:6190)
Japan · Delayed Price · Currency is JPY 338.00
-4.00 (-1.17%)
Aug 27, 2026, 3:30 PM JST
PhoenixBio Market Cap
PhoenixBio has a market cap or net worth of 1.39 billion as of August 27, 2026. Its market cap has decreased by -15.56% in one year.
Market Cap
1.39B
Enterprise Value
587.01M
Revenue
1.42B
Ranking
n/a
PE Ratio
92.79
Stock Price
338.00
ChartMarket Cap Chart
Since March 18, 2016, PhoenixBio's market cap has decreased from 8.06B to 1.39B, a decrease of -82.72%. That is a compound annual growth rate of -15.47%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 27, 2026 | 1.39B | -29.34% |
| Dec 30, 2025 | 1.97B | 47.38% |
| Dec 30, 2024 | 1.34B | -23.59% |
| Dec 29, 2023 | 1.75B | -25.42% |
| Dec 30, 2022 | 2.35B | 39.61% |
| Dec 30, 2021 | 1.68B | -13.26% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| TMS Co., Ltd. | 4.98B |
| J-Pharma | 4.93B |
| Ribomic | 4.69B |
| Kohjin Bio | 4.34B |
| Transgenic Group | 4.20B |
| Kringle Pharma | 3.66B |
| Human Metabolome Technologies | 3.59B |
| Modalis Therapeutics | 3.44B |